iOnctura Funding News – iOnctura Secures €80 Mn Series B Funding

Read also - SLAY funding news – Germany-based SLAY Secures $5Million in Seed Funding

Financing will be used to advance the development of roginolisib for uveal melanoma, a very rare eye cancer with no effective treatment available. Eye melanoma represents one of the most appropriately rapidly growing areas and is projected to reach quite appreciable value by 2032—it is expected that it will peak at USD 9.56B. Roginolisib showed long-term safety and promising efficacy in UM, sustaining clinical activity over many months in the Phase Ib clinical trial. Full results will be announced within the next few months.

Read also - DealCircle funding news – Hamburg-based DealCircle Raises 7-figure funding

Catherine Pickering, Chief Executive Officer, iOnctura, said: "This financing is validation of iOnctura's approach to developing precision cancer treatments with maximum clinical impact. These therapies have the potential to significantly prolong the healthspan of patients suffering with neglected cancer types, such as uveal melanoma. We are pleased to welcome our new investors Syncona and the EIC Fund alongside our existing strong syndicate. Their experience will be invaluable as we look to advance our pipeline and take iOnctura to its next stage of growth."

Roel Bulthuis, Managing Partner and Head of Investments at Syncona and Board member of iOnctura, added: "iOnctura represents a compelling opportunity to invest in line with our strategy and capital allocation focus in a clinical-stage company, and take a promising lead programme through to late-stage development. To date, no company has been able to successfully target this well-known cancer pathway with sufficient precision. By allosterically modulating PI3Kδ, iOnctura has achieved a new level of precision and could be the first company to develop a clinically meaningful medicine targeting this pathway. Its programmes have potential utility across a range of cancers, which we are supporting the company to unlock through a refined clinical strategy."

About iOnctura

Founded in 2017, iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families.